Suspension of trading

NeuBase Therapeutics, Inc. Stock Nasdaq

NBSE

US64132K2015

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 23:30:00 10/05/2024 +03			5-day change	1st Jan Change
0.3780 ^USD	-3.20%		-.--%	-

08/01/25	Neubase Therapeutics, Inc. Announces Resignation of Todd P. Branning as Chief Financial Officer	CI
08/01/25	Neubase Therapeutics, Inc. Announces Resignation of Todd P. Branning as Interim Chief Executive Officer	CI

Valuation: NeuBase Therapeutics, Inc.

Market Cap	1.28M 1.12M 1.03M 950K 1.79M 123M 1.83M 12.32M 4.84M 60.23M 4.8M 4.69M 207M	P/E 2023 *	-	P/E 2024 *	-
Enterprise Value	1.28M 1.12M 1.03M 950K 1.79M 123M 1.83M 12.32M 4.84M 60.23M 4.8M 4.69M 207M	EV / Sales 2023 *	-	EV / Sales 2024 *	-
Free-Float	86.62%	Yield 2023 *	-	Yield 2024 *	-

* Estimated data More valuation ratios

Latest news : NeuBase Therapeutics, Inc.

08/01/25	Neubase Therapeutics, Inc. Announces Resignation of Todd P. Branning as Chief Financial Officer	CI
08/01/25	Neubase Therapeutics, Inc. Announces Resignation of Todd P. Branning as Interim Chief Executive Officer	CI
27/06/24	NeuBase Therapeutics, Inc. Announces Board Resignations	CI
29/05/24	NeuBase Therapeutics, Inc. announced that it has received $0.000001 million in funding	CI

More news

Managers and Directors: NeuBase Therapeutics, Inc.

Manager	Title	Age	Since
Ron Sarkar PRN	Corporate Officer/Principal	-	01/11/2021

Director	Title	Age	Since
Todd Branning BRD	Director/Board Member	56	04/01/2025

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NEUBASE THERAPEUTICS, INC.	-3.20%	-.--%	-	-	1.39M
LONZA GROUP AG	-1.29%	-2.54%	-0.35%	+4.30%	49.7B
REVOLUTION MEDICINES, INC.	+3.90%	-2.60%	+384.79%	+598.27%	38.09B
BEONE MEDICINES AG	-1.70%	+3.03%	+11.77%	+58.93%	35.29B
IQVIA HOLDINGS INC.	-2.01%	-1.30%	+30.02%	-6.71%	35.13B
CELLTRION, INC.	+0.06%	+1.56%	+4.41%	+27.42%	27.22B
ASCENDIS PHARMA A/S	+0.46%	-5.24%	-	-	16.14B
MEDPACE HOLDINGS, INC.	-0.04%	+0.42%	+70.80%	+121.10%	15.36B
EUROFINS SCIENTIFIC SE	+1.12%	+2.15%	+16.24%	+19.12%	13.89B
ICON PUBLIC LIMITED COMPANY	0.00%	+0.73%	+18.02%	-30.96%	13.02B
Average	-0.27%	-0.57%	+66.96%	+98.93%	27.09B
Weighted average by Cap.	-0.09%	-0.64%	+78.08%	+119.96%

See all sector performances

NeuBase Therapeutics, Inc. is a United States-based preclinical-stage biotechnology company. It is developing a modular peptide-nucleic acid (PNA) antisense oligo (PATrOL) platform to address genetic diseases, with a single, cohesive approach. The Companyâ€™s programs are NT-0100 in HD, NT-0200 in myotonic dystrophy type 1 (DM1) and NT-0300 in KRAS-driven cancers. The NT-0100 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the HD DNA or RNA. The NT-0200 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the DM1 disease RNA. The NT-0300 program is a PATrOL-enabled therapeutic program being developed to target the mutated KRAS gene. It uses its platform to address diseases which have a genetic source, with an initial focus on gene silencing in DM1, Huntingtonâ€™s disease (HD), and oncology and in gene editing applications.

Employees

Sector

Biotechnology & Medical Research

More about the company